Lexicon Pharmaceuticals, Inc. (LXRX) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low4.8·High4.8
P/FCF
N/A
—
5yr avg: N/A
30Y Low4.3·High19.2
P/B Ratio
↓
7.26
↑+115% vs avg
5yr avg: 3.38
30Y Low1.0·High20.0
ROE
↑
-39.7%
↓+62% vs avg
5yr avg: -105.9%
30Y Low-168%·High111%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low1.7·High48.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LXRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lexicon Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $955M | $418M | $236M | $338M | $317M | $574M | $379M | $485M | $703M | $1.0B | $1.4B |
| Enterprise Value | $983M | $445M | $278M | $422M | $325M | $512M | $266M | $695M | $788M | $975M | $1.2B |
| P/E Ratio → | -15.36 | — | — | — | — | — | — | 3.74 | — | — | — |
| P/S Ratio | 19.18 | 8.38 | 7.60 | 281.00 | 2277.34 | 1925.73 | 15.80 | 1.50 | 11.12 | 11.51 | 17.24 |
| P/B Ratio | 7.26 | 3.88 | 1.62 | 3.63 | 2.70 | 5.05 | 2.42 | 4.14 | — | 19.96 | 9.13 |
| P/FCF | — | — | — | — | — | — | — | 4.26 | — | — | — |
| P/OCF | — | — | — | — | — | — | — | 4.26 | — | — | — |
P/E links to full P/E history page with 30-year chart
LXRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.94 | 8.95 | 350.44 | 2341.72 | 1718.40 | 11.07 | 2.16 | 12.46 | 10.79 | 14.30 |
| EV / EBITDA | — | — | — | — | — | — | — | 4.79 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 4.80 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 6.11 | — | — | — |
LXRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Lexicon Pharmaceuticals, Inc. earns an operating margin of -98.2%. Operating margins have expanded from -14265.0% to -98.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -39.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.4% | 99.4% | 98.0% | -4798.0% | -37681.3% | -18371.8% | 92.0% | 99.0% | 96.1% | 97.9% | -96.8% |
| Operating Margin | -98.2% | -98.2% | -634.2% | -14265.0% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% |
| Net Profit Margin | -101.1% | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.7% | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 111.1% | — | -123.2% | -63.8% |
| ROA | -20.8% | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.8% | 37.1% | -33.5% | -28.3% | -25.0% |
| ROIC | -22.7% | -22.7% | -81.1% | -85.1% | -85.0% | -137.9% | -19.3% | 32.4% | — | — | — |
| ROCE | -23.4% | -23.4% | -87.4% | -93.1% | -70.5% | -64.1% | -18.8% | 47.2% | -36.9% | -43.9% | -32.5% |
LXRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $28M ($62M total debt minus $34M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.58 | 0.58 | 0.74 | 1.14 | 0.47 | 0.02 | 0.08 | 2.11 | — | 4.72 | 0.64 |
| Debt / EBITDA | — | — | — | — | — | — | — | 1.70 | — | — | — |
| Net Debt / Equity | — | 0.26 | 0.29 | 0.90 | 0.08 | -0.54 | -0.73 | 1.80 | — | -1.25 | -1.56 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 1.45 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | 1.85 | — | — | — |
| Interest Coverage | -5.87 | -5.87 | -11.86 | -13.00 | -36.14 | -108.59 | -3.03 | 7.00 | -4.80 | -18.42 | -19.02 |
LXRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lexicon Pharmaceuticals, Inc.'s current ratio of 4.88x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.60x to 4.88x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.88 | 4.88 | 5.44 | 5.60 | 6.08 | 4.02 | 3.37 | 5.17 | 4.72 | 2.59 | 2.17 |
| Quick Ratio | 4.87 | 4.87 | 5.44 | 5.58 | 6.08 | 4.02 | 3.37 | 5.10 | 4.59 | 2.58 | 2.17 |
| Cash Ratio | 4.61 | 4.61 | 5.26 | 5.39 | 5.97 | 3.92 | 3.25 | 4.16 | 4.36 | 2.50 | 2.10 |
| Asset Turnover | — | 0.27 | 0.10 | 0.01 | 0.00 | 0.00 | 0.12 | 0.77 | 0.22 | 0.21 | 0.18 |
| Inventory Turnover | 0.98 | 0.98 | 2.67 | 154.78 | — | — | — | 0.76 | 0.53 | 0.97 | — |
| Days Sales Outstanding | — | 17.47 | 40.79 | 306.19 | 73.53 | 17.15 | 6.01 | 64.07 | 34.21 | 19.50 | 32.81 |
LXRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lexicon Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 26.7% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 23.5% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.7% | 0.2% | 0.3% | 0.5% | 0.3% | 0.2% | 0.1% | 0.2% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.7% | 0.2% | 0.3% | 0.5% | 0.3% | 0.2% | 0.1% | 0.2% | 0.0% |
| Shares Outstanding | — | $363M | $320M | $221M | $166M | $146M | $111M | $117M | $106M | $105M | $104M |
Peer Comparison
Compare LXRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LXRXYou | $955M | -15.4 | — | — | 99.4% | -98.2% | -39.7% | -22.7% | — |
 ARDX | $2B | -24.5 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 CORT | $9B | 97.2 | 180.8 | 60.4 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
 INVA | $2B | 6.9 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PTGX | $7B | -56.1 | — | 131.9 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 ACAD | $4B | 9.6 | 26.3 | 36.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 AGIO | $2B | -4.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RARE | $3B | -5.0 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 MDGL | $12B | -39.9 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 ELAN | $12B | -50.8 | 16.5 | 42.0 | 43.5% | 5.3% | -3.7% | 1.9% | 4.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
LXRX — Frequently Asked Questions
Quick answers to the most common questions about buying LXRX stock.
What is Lexicon Pharmaceuticals, Inc.'s P/E ratio?
Lexicon Pharmaceuticals, Inc.'s current P/E ratio is -15.4x. The historical average is 3.7x.
What is Lexicon Pharmaceuticals, Inc.'s ROE?
Lexicon Pharmaceuticals, Inc.'s return on equity (ROE) is -39.7%. The historical average is -52.8%.
Is LXRX stock overvalued?
Based on historical data, Lexicon Pharmaceuticals, Inc. is trading at a P/E of -15.4x. Compare with industry peers and growth rates for a complete picture.
What are Lexicon Pharmaceuticals, Inc.'s profit margins?
Lexicon Pharmaceuticals, Inc. has 99.4% gross margin and -98.2% operating margin.